Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer

BACKGROUND: This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Li‐Yue, Cen, Wen‐Jian, Tang, Wen‐Ting, Long, Ya‐Kang, Yang, Xin‐Hua, Ji, Xiao‐Meng, Yang, Jiao‐Jiao, Zhang, Ren‐Jing, Wang, Fang, Shao, Jian‐Yong, Du, Zi‐Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495280/
https://www.ncbi.nlm.nih.gov/pubmed/34469045
http://dx.doi.org/10.1002/cam4.4197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495280/
https://www.ncbi.nlm.nih.gov/pubmed/34469045
http://dx.doi.org/10.1002/cam4.4197

Ejemplares similares